Antitumor effects of baculovirus-infected dendritic cells against human pancreatic carcinoma

Tjia SY, zu Altenschildesche GM, Doerfler W . Autographa californica nuclear polyhedrosis virus (AcNPV) DNA does not persist in mass cultures of mammalian cells. Virology 1983; 125: 107–117.

Hofmann C, Sandig V, Jennings G, Rudolph M, Schlag P, Strauss M . Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92: 10099–10103.

Condreay JP, Witherspoon SM, Clay WC, Kost TA . Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector. Proc Natl Acad Sci USA 1999; 96: 127–132.

Suzuki T, Chang MO, Kitajima M, Takaku H . Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses. Cellular Immunol 2010; 262: 35–43.

Hofmann C, Strauss M . Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther 1998; 5: 531–536.

Nasta F, Ubald V, Pace L, Doria G, Pioli C . Cytotoxic T-lymphocyte antigen-4 inhibits GATA-3 but not T-bet mRNA expression during T helper cell differentiation. Immunology 2006; 117: 358–367.

Molinari P, Crespo MI, Gravisacol MJ, Taboga O, Moron G . Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses. PLoS One 2011; 6: e24108.

Beck NB, Sidhu JS, Omiecinski CJ . Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes. Gene Ther 2000; 7: 1274–1283.

Gronowski AM, Hilbert DM, Sheehan KCF, Schreiber RD . Baculovirus stimulates antiviral effects in mammalian cells. J Virol 1999; 73: 9944–9951.

Abe T, Takahashi H, Hamazaki H, Miyano-Kurosaki N, Matsuura Y, Takaku H . Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 2003; 171: 1133–1139.

Abe T, Hemmi H, Miyamoto H, Moriishi K, Tamura S, Takaku H et al. Involvement of the Toll-Like Receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 2005; 79: 2847–2858.

Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S et al. Baculovirus induces type I interferon production through Toll-Like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol 2009; 83: 7629–7640.

Abe T, Matsuura Y . Host innate immune responses induced by baculovirus in mammals. Curr Gene Ther 2010; 10: 226–231.

Kitajima M, Abe T, Miyano-Kurosaki N, Taniguchi M, Nakayama T, Takaku H . Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus. Mol Ther 2008; 16: 261–268.

Nishibe Y, Kaneko H, Suzuki H, Abe T, Matsuura Y, Takaku H . Baculovirus-mediated interferon alleviates dimethylnitrosamine-induced liver cirrhosis symptoms in a murine model. Gene Ther 2008; 15: 990–997.

Suzuki T, Oo Chang M, Kitajima M, Takaku H . Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells. Cell Mol Immunol 2010; 7: 440–446.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 11: 1200–1210.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al. FOLFIRINOX versus gemcitabine for metasrtatic pancreatic cancer. N Engl J Med 2011; 364: 1817–1825.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.

Salmons B, Brandtner EM, Hettrich K, Wagenknecht W, Volkert B, Fischer S et al. Encapsulated cells to focus the metabolic activation of anticancer drugs. Curr Opin Mol Ther. 2010; 12: 450–460.

Laheru D, Jaffee E . Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 2005; 5: 459–467.

Ardavin C, Amigorena S, Reis e Sousa C . Dendritic cells: immunobiology and cancer immunotherapy. Immunity 2004; 20: 17–23.

Banchereau J, Palucka AK . Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296–306.

Steinman RM, Banchereau J . Taking dendritic cells intomedicine. Nature 2007; 449: 419–426.

Gong J, Koido S, Calderwood SK . Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines 2007; 7: 1055–1068.

Koido S, Homma S, Hara E, Namiki Y, Ohkusa T, Gong J et al. Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells. J Biomed Biotechnol 2010; 2010: 752381.

Cheever MA, Higano CS . PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2001; 17: 3520–3526.

Di Lorenzo G, Buonerba C, Kantoff PW . Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011; 8: 551–561.

Pecher G, Häring H, Kaiser L, Thiel E . Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol, Immunother 2002; 51: 669–673.

Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008; 6: 955–964.

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol, Immunother 2011; 60: 669–673.

Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K et al. Clinical and immunologic evaluation of dendriticcell-based immunotherapy in combination with gemcitabine and/or S-1 in the patients with advanced pancreatic carcinoma. Pancreas 2012; 41: 195–205.